Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
- 11 November 2026
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Abstract
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.Funding Information
- National Institutes of Health (R01AR062207)
- National Institutes of Health (R01AR061484)
- National Institutes of Health (R01AR076900)
- National Institutes of Health (R01AR078035)
- National Institutes of Health (R01NS070328)
This publication has 85 references indexed in Scilit:
- The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseasesJournal of Cellular Physiology, 2021
- Diagnosis and Treatment of Hip and Knee OsteoarthritisJAMA, 2021
- Experimental Osteoarthritis Models in Mice2014
- Autophagy: A Critical Regulator of Cellular Metabolism and HomeostasisMolecules and Cells, 2013
- Osteoarthritis: A disease of the joint as an organArthritis & Rheumatism, 2012
- Matrix metalloproteinase 13–deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte developmentArthritis & Rheumatism, 2009
- The impact of anterior cruciate ligament injury on lubricin metabolism and the effect of inhibiting tumor necrosis factor α on chondroprotection in an animal modelArthritis & Rheumatism, 2009
- Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled studyArthritis Care & Research, 2009
- In vivo suppression of early experimental osteoarthritis by interleukin‐1 receptor antagonist using gene therapyArthritis & Rheumatism, 1997
- Chondroprotective effect of intraarticular injections of interleukin‐1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase‐1 expressionArthritis & Rheumatism, 1996